Skip to main content
SpringerLink
Log in

Expression of GSK3B in peripheral blood of patients with Parkinson’s disease

  • genomics. Transcriptomics
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons. Detecting changes in gene expression in untreated de novo patients with PD is important for understanding the disease pathogenesis and for identifying biomarkers of the preclinical stage of PD. In this study, the expression of the glycogen synthase kinase-3 beta gene (GSK3B) was investigated in the peripheral blood of several groups of neurological patients using reverse transcription reaction and real-time PCR. Our results suggest that the GSK3B expression level cannot serve as a biomarker for early stages of PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

PD:

Parkinson’s disease

AD:

Alzheimer’s disease

ICD-10:

International Classification of Diseases; 10th revision

PCR:

polymerase chain reaction

GSK-3b:

glycogen synthase kinase-3 beta

References

  1. Lesage S., Brice A. 2009. Parkinson’s disease: From monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48–R59.

    Article  PubMed  CAS  Google Scholar 

  2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415–455.

    Article  PubMed  CAS  Google Scholar 

  3. Cookson M.R., Hardy J., Lewis P.A. 2008. Genetic neuropathology of Parkinson’s disease. Int. J. Clin. Exp. Pathol. 1, 217–231.

    PubMed  CAS  Google Scholar 

  4. Michell A.W., Lewis S.J.G., Foltynie T., Barker R.A. 2004. Biomarkers and Parkinson’s disease. Brain. 127, 1693–1705.

    Article  PubMed  CAS  Google Scholar 

  5. Miller D.W., Hague S.M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M.R., Singleton A.B. 2004. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology. 62, 1835–1838.

    PubMed  CAS  Google Scholar 

  6. Sunada Y., Saito F., Matsumura K., Shimizu T. 1998. Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci. Lett. 254, 180–182.

    Article  PubMed  CAS  Google Scholar 

  7. Schulz J.B., Beal M.F. 1994. Mitochondrial dysfunction in movement disorders. Curr. Opin. Neurol. 7, 333–339.

    Article  PubMed  CAS  Google Scholar 

  8. Barbanti P., Fabbrini G., Ricci A., Cerbo R., Bronzetti E., Caronti B., Calderaro C., Felici L., Stocchi F., Meco G., Amenta F., Lenzi G.L. 1999. Increased expression of dopamine receptors on lymphocytes in Parkinson’s disease. Mov. Disord. 14, 764–771.

    Article  PubMed  CAS  Google Scholar 

  9. Petrozzi L., Lucetti C., Gambaccini G., Bernardini S., Del Dotto P., Migliore L., Scarpato R., Bonuccelli U. 2001. Cytogenetic analysis oxidative damage in lymphocytes of Parkinson’s disease patients. Neurol. Sci. 22, 83–84.

    Article  PubMed  CAS  Google Scholar 

  10. Scherzer C.R., Eklund A.C., Morse L.J., et al. 2007. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc. Natl. Acad. Sci. U.S.A. 104, 955–960.

    Article  PubMed  CAS  Google Scholar 

  11. Armentero M.T., Sinforiani E., Ghezzi C., et al. 2010. Peripheral expression of key regulatory kinases in Alzheimer’s disease and Parkinson’s disease. Neurobiol. Aging. DOI: 10.1016/j.neurobiolaging.2010.01.004.

  12. Woodgett J.R. 2004. Glycogen synthase kinase-3. In: Encyclopedia of Biological Chemistry. Eds. Lennarz W.J., Lane M.D. San Diego, CA: Elsevier, vol. 2, pp. 255–260.

    Chapter  Google Scholar 

  13. Morfini G., Szebenyi G., Elluru R., Ratner N., Brady S.T. 2002. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 21, 281–293.

    Article  PubMed  CAS  Google Scholar 

  14. Pigino G., Morfini G., Pelsman A., Mattson M.P., Brady S.T., Busciglio J. 2003. Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 23, 4499–4508.

    PubMed  CAS  Google Scholar 

  15. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., Raman R., Davies P., Masliah E., Williams D.S., Goldstein L.S.B. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science. 307, 1282–1288.

    Article  PubMed  CAS  Google Scholar 

  16. Shah S.B., Nolan R., Davis E., Stokin G.B., Niesman I., Canto I., Glabe C., Goldstein L.S.B. 2009. Examination of potential mechanisms of amyloid-induced defects in neuronal transport. Neurobiol. Dis. 36, 1–25.

    Article  Google Scholar 

  17. Jope R.S., Johnson G.V.W. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95–102.

  18. Buttrick G.J., Wakefield J.G. 2008. PI3-K and GSK-3: Akt-ing together with microtubules. Cell Cycle. 7, 262–265.

    Article  Google Scholar 

  19. Duronio V. 2008. The life of a cell: Apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 415, 333–344.

    Article  PubMed  CAS  Google Scholar 

  20. Ferrer I., Barrachina M., Puig B. 2002. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy, and corticobasal degeneration. Acta Neuropathol. 104, 583–591.

    PubMed  CAS  Google Scholar 

  21. Hoshi M., Takashima A., Noguchi K., Murayama M., Sato M., Kondo S., Saitoh Y., Ishiguro K., Hoshino T., Imahori K. 1996. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc. Natl. Acad. Sci. U.S.A. 93, 2719–2723.

    Article  PubMed  CAS  Google Scholar 

  22. Luna-Muñoz J., García-Sierra F., Falcón V., Menéndez I., Chávez-Macias L., Mena R. 2005. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer’s disease. J. Alzheimer’s Dis. 8, 29–41.

    Google Scholar 

  23. Valencia A., Reeves P.B., Sapp E., Li X., Alexander J., Kegel K.B., Chase K., Aronin N., DiFiglia M. 2009. Mutant huntingtin and glycogen synthase kinase 3-accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington’s disease. J. Neurosci. Res. 88, 179–190.

    Article  Google Scholar 

  24. Ross C.A., Poirier M.A. 2004. Protein aggregation and neurodegenerative disease. Nature Med. 10, S10–S17.

    Article  PubMed  Google Scholar 

  25. Nagao M., Hayashi H. Glycogen synthase kinase-3beta is associated with Parkinson’s disease. Neurosci. Lett. 449, 103–107.

  26. Bové J., Prou D., Perier C., Przedborski S. 2005. Toxin-induced models of Parkinson’s disease. NeuroRx: J. Am. Soc. Exp. NeuroTher. 2, 484–494.

    Google Scholar 

  27. Hye A., Kerr F., Archer N., Foy C., Poppe M., Brown R., Hamilton G., Powell J. 2004. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer’s disease. Neurosci. Lett. 373, 1–4.

    Article  Google Scholar 

  28. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55, 181–184.

    Article  PubMed  CAS  Google Scholar 

  29. Applied Biosystems. 2001. User Bulletin No. 2: ABI Prism 7700 Sequence Detection System.

  30. Warrington J.A., Nair A., Mahadevappa M., Tsyganskaya M. 2000. Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. Physiol. Genomics. 2, 143–147.

    PubMed  CAS  Google Scholar 

  31. DeKosky S.T., Marek K. Looking backward to move forward: Early detection of neurodegenerative disorders. Science. 302, 830–834.

  32. Bychkov E., Ahmed M.R., Dalby K.N., Gurevich E.V. 2007. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J. Neurochem. 102, 699–711.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, 123182, Russia

    E. V. Filatova, M. I. Shadrina, P. A. Slominsky & S. A. Limborska

  2. Scientific Center of Neurology, Russian Academy of Medical Science, Moscow, 125367, Russia

    A. V. Karabanov, S. N. Illarioshkin & I. A. Ivanova-Smolenskaya

Authors
  1. E. V. Filatova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. I. Shadrina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. V. Karabanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. A. Slominsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. N. Illarioshkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. A. Ivanova-Smolenskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. A. Limborska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. V. Filatova.

Additional information

Original Russian Text © E.V. Filatova, M.I. Shadrina, A.V. Karabanov, P.A. Slominsky, S.N. Illarioshkin, I.A. Ivanova-Smolenskaya, S.A. Limborska, 2011, published in Molekulyarnaya Biologiya, 2011, Vol. 45, No. 3, pp. 459–463.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filatova, E.V., Shadrina, M.I., Karabanov, A.V. et al. Expression of GSK3B in peripheral blood of patients with Parkinson’s disease. Mol Biol 45, 417–420 (2011). https://doi.org/10.1134/S0026893311020063

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893311020063

Keywords

Search

Navigation